Stevens Matthew P, Tan Sarah E, Horvath Leonie, Fairley Christopher K, Garland Suzanne M, Tabrizi Sepehr N
Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Carlton, Victoria.
Commun Dis Intell Q Rep. 2008 Mar;32(1):77-81. doi: 10.33321/cdi.2008.32.10.
A Chlamydia trachomatis (CT) variant, harbouring a 377 bp deletion in the cryptic plasmid, recently identified in Europe, has caused false-negative reporting of CT infections by various assays. This report is aimed at identifying whether this variant is present among clients of a sexual health clinic, or antenatal screening patients in Melbourne. Two hundred CT-positive specimens (by BDProbeTec ET assay) from Melbourne Sexual Health Centre (August 2005-November 2006) were tested by COBAS TaqMan 48 PCR assay. Discrepancies were tested by an in-house real-time (Re-Ti) polymerase chain reaction (PCR) assay, amplifying a 274-bp region of the omp1 gene. Additionally, 1,071 consecutive specimens from antenatal screening patients at the Royal Women's Hospital (December 2006-April 2007) were tested by COBAS TaqMan 48 and omp1 Re-Ti PCR. The CT variant was not detected among the 200 CT-positive specimens (95% confidence interval 0-2.3%). Three tested CT-negative by COBAS TaqMan 48, omp1 Re-Ti PCR and CT mutant-specific PCR, suggesting sample degradation or differential assay sensitivity. Of the 1,071 antenatal screening specimens, 56 tested CT-positive and 1,015 CT-negative by COBAS TaqMan 48. All of the CT-negatives tested negative by omp1 Re-Ti PCR (95% confidence interval 0-0.5%), with 51 of 56 CT-positives testing positive. These findings show there were no CT variants among attendees of a Melbourne sexual health clinic, nor among antenatal screening patients. It is likely that the variant strain has not yet entered circulation in these populations. However, given the current upsurge in urogenital CT-infections, continued surveillance is necessary to ensure timely detection of this variant, should it be introduced into the population.
一种沙眼衣原体(CT)变体,其隐蔽质粒中存在377 bp的缺失,最近在欧洲被发现,该变体导致各种检测方法对CT感染的假阴性报告。本报告旨在确定这种变体是否存在于一家性健康诊所的客户或墨尔本产前筛查患者中。对墨尔本性健康中心(2005年8月至2006年11月)的200份CT阳性标本(通过BDProbeTec ET检测)进行了COBAS TaqMan 48 PCR检测。通过内部实时(Re-Ti)聚合酶链反应(PCR)检测差异,扩增omp1基因的274 bp区域。此外,对皇家妇女医院(2月至4月)产前筛查患者的1071份连续标本进行了COBAS TaqMan 48和omp1 Re-Ti PCR检测。在200份CT阳性标本中未检测到CT变体(95%置信区间0-2.3%)。通过COBAS TaqMan 48、omp1 Re-Ti PCR和CT突变体特异性PCR检测的3份标本为CT阴性,提示样本降解或检测灵敏度差异。在1071份产前筛查标本中,通过COBAS TaqMan 48检测,56份为CT阳性,1015份为CT阴性。所有CT阴性标本通过omp1 Re-Ti PCR检测均为阴性(95%置信区间0-0.5%),56份CT阳性标本中有51份检测为阳性。这些结果表明,墨尔本性健康诊所的就诊者和产前筛查患者中均不存在CT变体。该变体菌株可能尚未在这些人群中传播。然而,鉴于目前泌尿生殖系统CT感染的激增,有必要持续监测,以确保在该变体引入人群时能及时检测到。